Farallon Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Farallon Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$695M	Buy	9,365,463 +367,000	+4%	+$26.6M	3.96%	6
2025 Q4	$688M	Buy	8,998,463 +806,463	+10%	+$52.9M	3.12%	10
2025 Q3	$425M	Buy	8,192,000 +292,000	+4%	+$14.2M	1.74%	19
2025 Q2	$341M	Buy	7,900,000 +2,169,000	+38%	+$78.9M	1.43%	29
2025 Q1	$198M	Buy	5,731,000 +1,536,000	+37%	+$51.8M	0.95%	37
2024 Q4	$115M	Buy	4,195,000 +2,448,000	+140%	+$63.3M	0.51%	50
2024 Q3	$44.5M	Buy	+1,747,000	New	+$45.9M	0.2%	69
2024 Q1	–	Sell	-6,000	Closed	-$242K	–	176
2023 Q4	$242K	Buy	+6,000	New	+$180K	﹤0.01%	120

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Farallon Capital Management's BBIO Position: Q1 2026 in Review

Farallon Capital Management increased its BridgeBio Pharma (BBIO) stake by 4.1% in Q1 2026, buying an estimated $26.6M and bringing the position to 9,365,463 shares worth $695M. The position accounts for 3.96% of the portfolio, ranked #6.

Farallon Capital Management first reported a position in BBIO in Q4 2023 and has held it in 8 quarters since. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Farallon Capital Management held 9,365,463 shares of BridgeBio Pharma worth $695M as of Q1 2026.
Farallon Capital Management bought 367,000 BridgeBio Pharma shares in Q1 2026, an estimated $26.6M.
BridgeBio Pharma made up 3.96% of Farallon Capital Management's portfolio in Q1 2026, its #6 holding.
Farallon Capital Management first reported a position in BridgeBio Pharma in Q4 2023 and has held it in 8 quarters since.
457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.